Literature DB >> 10215508

Distinct glycolysis inhibitors determine retinal cell sensitivity to glutamate-mediated injury.

A C Rego1, F M Areias, M S Santos, C R Oliveira.   

Abstract

In this study, we analyzed how distinct glycolysis inhibitors influenced the redox status of retinal cells, used as a neuronal model. Three different approaches were used to inhibit glycolysis: the cells were submitted to iodoacetic acid (IAA), an inhibitor of glyceraldehyde 3-phosphate dehydrogenase, to 2-deoxy-glucose (DG) in glucose-free medium, which was used as a substitute of glucose, or in the absence of glucose. The redox status of the cells was evaluated by determining the reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide). By the analysis of dose-response curves of MTT reduction, IAA showed values of IC50 = 7.02 x 10(-5) M, whereas DG showed values of IC50 = 7.42 x 10(-4) M. Upon 30 min-incubation, glucose deprivation, per se, did not significantly affect MTT reduction. We also evaluated the reduction of MTT as an indicator of cell injury by exposing the cells to 100 microM glutamate during the decrement of glycolysis function. In the presence of glutamate, for 2 h, there was a decrease in MTT reduction, which was potentiated in the presence of DG (10-20% decrease), in the presence of IAA (about 30% decrease) or in glucose-free medium (about 30% decrease). Major changes observed by the MTT assay, upon exposure to glutamate, indicative of changes in the redox status of retinal cells, were concomitant with variations in intracellular ATP. Under glucose deprivation, endogenous ATP decreased significantly from 38.9+/-4.4 to 13.3+/-0.7 nmol/mg protein after exposure to 100 microM glutamate. The results support a different vulnerability of retinal cells after being exposed to distinct forms of glycolysis inhibition.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215508     DOI: 10.1023/a:1020977331372

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  34 in total

1.  Failure to maintain glycolysis in anoxic nerve terminals.

Authors:  R A Kauppinen; D G Nicholls
Journal:  J Neurochem       Date:  1986-12       Impact factor: 5.372

2.  Acute neurotoxicity of L-glutamate induced by impairment of the glutamate uptake system.

Authors:  S Okazaki; Y Nishida; H Kawai; S Saito
Journal:  Neurochem Res       Date:  1996-10       Impact factor: 3.996

3.  Reduction of a tetrazolium salt and superoxide generation in human tumor cells (HeLa).

Authors:  R H Burdon; V Gill; C Rice-Evans
Journal:  Free Radic Res Commun       Date:  1993

4.  Reduced glucose metabolism enhances the glutamate-evoked release of arachidonic acid from striatal neurons.

Authors:  R J Williams; M Maus; N Stella; J Glowinski; J Premont
Journal:  Neuroscience       Date:  1996-09       Impact factor: 3.590

5.  Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina.

Authors:  G D Zeevalk; W J Nicklas
Journal:  J Pharmacol Exp Ther       Date:  1990-06       Impact factor: 4.030

Review 6.  Tetrazolium salts and formazans.

Authors:  F P Altman
Journal:  Prog Histochem Cytochem       Date:  1976

7.  Glutamate efflux via the reversal of the sodium-dependent glutamate transporter caused by glycolytic inhibition in rat cultured astrocytes.

Authors:  T Gemba; T Oshima; M Ninomiya
Journal:  Neuroscience       Date:  1994-12       Impact factor: 3.590

8.  Glycolysis and brain function: [K+]o stimulation of protein synthesis and K+ uptake require glycolysis.

Authors:  P Lipton; K Robacker
Journal:  Fed Proc       Date:  1983-09

9.  Inhibition of glycolysis by 2-DG increases [Ca2+]i in pulmonary arterial smooth muscle cells.

Authors:  R T Bright; C G Salvaterra; L J Rubin; X J Yuan
Journal:  Am J Physiol       Date:  1995-08

10.  The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by beta-amyloid peptides.

Authors:  M S Shearman; S R Hawtin; V J Tailor
Journal:  J Neurochem       Date:  1995-07       Impact factor: 5.372

View more
  7 in total

1.  D-beta-hydroxybutyrate prevents glutamate-mediated lipoperoxidation and neuronal damage elicited during glycolysis inhibition in vivo.

Authors:  Jana Mejía-Toiber; Teresa Montiel; Lourdes Massieu
Journal:  Neurochem Res       Date:  2006-11-18       Impact factor: 3.996

Review 2.  Back to the future with phenotypic screening.

Authors:  Marguerite Prior; Chandramouli Chiruta; Antonio Currais; Josh Goldberg; Justin Ramsey; Richard Dargusch; Pamela A Maher; David Schubert
Journal:  ACS Chem Neurosci       Date:  2014-06-05       Impact factor: 4.418

3.  Chemical modification of the multitarget neuroprotective compound fisetin.

Authors:  Chandramouli Chiruta; David Schubert; Richard Dargusch; Pamela Maher
Journal:  J Med Chem       Date:  2011-12-20       Impact factor: 7.446

4.  The acute inhibition of enteric glial metabolism with fluoroacetate alters calcium signaling, hemichannel function, and the expression of key proteins.

Authors:  Jonathon L McClain; Brian D Gulbransen
Journal:  J Neurophysiol       Date:  2016-10-26       Impact factor: 2.714

5.  A novel approach to screening for new neuroprotective compounds for the treatment of stroke.

Authors:  Pamela Maher; Karmen F Salgado; Justin A Zivin; Paul A Lapchak
Journal:  Brain Res       Date:  2007-08-09       Impact factor: 3.252

6.  Using Plants as a Source of Potential Therapeutics for the Treatment of Alzheimer's Disease.

Authors:  Pamela A Maher
Journal:  Yale J Biol Med       Date:  2020-06-29

7.  Neuroprotective actions of methylene blue and its derivatives.

Authors:  Ethan Poteet; Ali Winters; Liang-Jun Yan; Kyle Shufelt; Kayla N Green; James W Simpkins; Yi Wen; Shao-Hua Yang
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.